US Patent

US7459554 — Imidazopyrazine tyrosine kinase inhibitors

Composition of Matter · Assigned to OSI Pharmaceuticals LLC · Expires 2026-11-24 · 1y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds of the formula and their pharmaceutically acceptable salts, which inhibit the IGF-1R enzyme.

USPTO Abstract

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q 1 and R 1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Drugs covered by this patent

Patent Metadata

Patent number
US7459554
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-11-24
Drug substance claim
Yes
Drug product claim
No
Assignee
OSI Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.